Placebo transdermal gel

DRUG2 trials

Sponsors

University of Zurich, Zynerba Pharmaceuticals, Inc.

Conditions

Fragile X SyndromeHypogonadismPre-frail Seniors

Phase 2

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

CompletedNCT03614663

Zynerba Pharmaceuticals, Inc.Fragile X Syndrome

Start: 2018-06-12End: 2020-06-14Updated: 2022-07-06

Phase 3

Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors

TerminatedNCT02419105

University of ZurichHypogonadism, Pre-frail Seniors

Start: 2015-09-30End: 2020-06-30Updated: 2020-06-18

Related Papers

Caregiver-perceived behavioral challenges in fragile X syndrome and implications for measuring treatment benefit in clinical trials

Journal of Patient-Reported Outcomes2026-04-01

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Journal of Neurodevelopmental Disorders2022-11-2560 citations

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial

BMJ Open2020-03-0116 citations